# Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus

> **NCT04233164** · EARLY_PHASE1 · COMPLETED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 47 (actual)

## Conditions studied

- Systemic Lupus Erythematous (SLE)

## Interventions

- **DRUG:** Solu-Medrol 1mg/kg
- **DRUG:** Solu-Medrol 250 mg

## Key facts

- **NCT ID:** NCT04233164
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-04
- **Primary completion:** 2022-05-03
- **Final completion:** 2022-05-03
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233164, "Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04233164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*